KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Accumulated Expenses (2016 - 2026)

Neogenomics filings provide 17 years of Accumulated Expenses readings, the most recent being $12.7 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 67.77% to $12.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.7 million, a 67.77% decrease, with the full-year FY2025 number at $47.6 million, down 23.8% from a year prior.
  • Accumulated Expenses hit $12.7 million in Q1 2026 for Neogenomics, down from $47.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $62.4 million in Q4 2024 to a low of $12.7 million in Q1 2026.
  • Median Accumulated Expenses over the past 5 years was $38.0 million (2022), compared with a mean of $35.6 million.
  • Biggest five-year swings in Accumulated Expenses: surged 252.76% in 2023 and later plummeted 67.77% in 2026.
  • Neogenomics' Accumulated Expenses stood at $15.1 million in 2022, then surged by 252.76% to $53.2 million in 2023, then grew by 17.46% to $62.4 million in 2024, then decreased by 23.8% to $47.6 million in 2025, then tumbled by 73.25% to $12.7 million in 2026.
  • The last three reported values for Accumulated Expenses were $12.7 million (Q1 2026), $47.6 million (Q4 2025), and $17.4 million (Q3 2025) per Business Quant data.